Chengdu Saijing Biopharmaceutical Technology

Chengdu Saijing Biopharmaceutical Technology is a clinical-stage biotechnology company based in Chengdu, China, focused on the discovery and development of innovative small molecule drugs for oncology. The company's research and development efforts primarily target cell cycle regulation and DNA damage repair pathways, with a pipeline featuring CDK4/6 inhibitors and PARP inhibitors. Its lead candidate, SJG-136, is being evaluated in clinical trials for the treatment of advanced solid tumors, including breast cancer. Saijing Biopharmaceutical aims to address unmet medical needs in the cancer space through the development of highly selective and potent therapeutic agents.